
    
      This is a randomized, double-blind, double-dummy, placebo and active-controlled
      (glimepiride), multi-center, parallel-group study to investigate the effect of JTT-851 on
      HbA1c and other ancillary efficacy parameters and to assess the safety, tolerability, and
      pharmacokinetics of JTT-851 in inadequately-controlled treatment-na√Øve or metformin-treated
      type 2 diabetic patients.
    
  